NCT01229007 - Study of Biostate® in Children With Hemophilia A | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2010

Primary Completion Date

July 31, 2014

Study Completion Date

July 31, 2014

Conditions

Hemophilia A

Interventions

BIOLOGICAL

Biostate

1 dose of 50 IU FVIII/kg body weight of Biostate administered intravenously on Day 1 in the PK component, followed by the Efficacy component for continuation of Biostate therapy, as required for a minimum of 50 exposure days.

Trial Locations (8)

64000

Study site, Monterrey

223040

Study site, Minsk

246040

Study site, Homyel

0179

Study Site, Tbilisi

01010

Study Site, Guatemala City

Unknown

Study Site, Beirut

Study Site, Dnipropetrovsk

Study Site, Lviv